Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of using remestemcel-L, an
ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product
(MSCs) delivered by targeted endoscopic delivery to treat people for medically refractory
ulcerative colitis.
This study will enroll adult patients with medically refractory ulcerative colitis who are
planning to switch biologic therapy or undergo colectomy as the next stage in their treatment
plan.